Advertisement
Skip to Content

Biogen Inc BIIB Stock Quote

| Rating as of

NASDAQ: BIIB

Last close prices updated as of Mar 30, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 275.13
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Value
  • Day Range 272.64  –  276.38
  • Year Range 187.16  –  311.88
  • Market Cap 39.7523 Bil
  • Volume / Avg 323.0 /  991,804.3
  • Price / Sales 3.95
  • Price / Book 2.97
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis BIIB

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Biogen's New Alzheimer's Drug Leqembi Further Supports Its Neurology-Based Wide Moat

Karen Andersen Sector Strategist

Business Strategy and Outlook

| Karen Andersen |

We think Biogen's specialty-market-focused drug portfolio and novel, neurology-focused pipeline create a wide economic moat. Biogen's strategy has its roots in the 2003 merger of Biogen (multiple sclerosis drug Avonex) and Idec (cancer drug Rituxan). While Rituxan is succumbing to biosimilar competition, Biogen is expanding its neurology portfolio beyond MS, including blockbuster neuromuscular disease drug Spinraza and several promising drugs, including Leqembi in Alzheimer's disease.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BIIB

Company Profile BIIB

Business Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Contact
225 Binney Street
Cambridge, MA, 02142
Industry Drug Manufacturers - General
Employees 8,725

Related Articles BIIB

FAQs for Biogen Inc Stock

No. BIIB does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

BIIB’s market cap is 39.75 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

BIIB’s stock style is Large Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

BIIB’s price/sales is 3.95.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

BIIB’s price/forward earnings is 13.18.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

BIIB’s price/book is 2.96.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See BIIB’s valuation ratios compared to the Market Index.

BIIB’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare BIIB’s historical performance against its industry peers and the overall market.